<?xml version="1.0" encoding="UTF-8"?>
<p>The World Health Organization interim guidance statement indicates daily administration of low-molecular weight heparins (LMWHs) or twice daily subcutaneous unfractionated heparin (UFH) for the prophylaxis of thrombotic events in COVID-19 patients [
 <xref rid="B41-jcm-09-02084" ref-type="bibr">41</xref>].
</p>
